RA Capital Discloses 10.3% Stake in Adicet Bio

TL;DR

**RA Capital just revealed a 10.3% stake in Adicet Bio, signaling a big institutional bet on the biotech.**

AI Summary

RA Capital Management, L.P., a major investment firm, along with its affiliates Peter Kolchinsky and RA Capital Healthcare Fund, L.P., reported a significant ownership stake in Adicet Bio, Inc. (NASDAQ: ACET) as of January 25, 2024. This filing indicates that RA Capital Management now beneficially owns 10.3% of Adicet Bio's common stock, totaling 7,200,000 shares. This matters to investors because a prominent institutional investor increasing or maintaining a large stake can signal confidence in the company's future prospects, potentially influencing other investors' perceptions and the stock price.

Why It Matters

A substantial stake by a well-known healthcare investor like RA Capital can be seen as a vote of confidence in Adicet Bio's drug development pipeline and long-term potential, potentially attracting more investor interest.

Risk Assessment

Risk Level: medium — While institutional ownership can be positive, the biotech sector itself carries inherent risks related to clinical trials and regulatory approvals.

Analyst Insight

A smart investor would research Adicet Bio's recent developments and pipeline, considering that a major healthcare-focused fund like RA Capital has taken a substantial stake, indicating potential long-term value.

Key Numbers

• 7,200,000 — Shares Owned (Total common stock shares of Adicet Bio beneficially owned by RA Capital Management, L.P. and its affiliates.)
• 10.3% — Ownership Percentage (The percentage of Adicet Bio, Inc.'s common stock beneficially owned by RA Capital Management, L.P. and its affiliates.)
• January 25, 2024 — Event Date (The date that triggered the requirement for this SC 13G filing.)

Key Players & Entities

• RA Capital Management, L.P. (company) — reporting person and investment firm
• Adicet Bio, Inc. (company) — subject company, a pharmaceutical preparations company
• Peter Kolchinsky (person) — group member associated with RA Capital
• RA Capital Healthcare Fund, L.P. (company) — group member associated with RA Capital
• 7,200,000 shares (dollar_amount) — total shares beneficially owned by RA Capital
• 10.3% (dollar_amount) — percentage of Adicet Bio's common stock owned by RA Capital
• January 25, 2024 (dollar_amount) — date of event requiring the filing

Forward-Looking Statements

• Adicet Bio's stock price may see increased stability or upward pressure due to significant institutional backing. (Adicet Bio, Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securiti

Filing Documents

• tm245013d1_sc13g.htm (SC 13G) — 79KB
• tm245013d1_ex99-1.htm (EX-99.1) — 6KB
• 0001104659-24-010651.txt ( ) — 87KB

(a)

Item 1(a). Name of Issuer: Adicet Bio, Inc. (the “Issuer”)

(b)

Item 1(b). Address of Issuer’s Principal Executive Offices: 200 Berkeley Street, 19th Floor, Boston, MA 02116

(a)

Item 2(a). Names of Persons Filing: The names of the persons filing this report (collectively, the “Reporting Persons”) are: RA Capital Management, L.P. (“RA Capital”) Peter Kolchinsky Rajeev Shah RA Capital Healthcare Fund, L.P. (the “Fund”)

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: The address of the principal business office of each of the Reporting Persons is: c/o RA Capital Management, L.P., 200 Berkeley Street, 18th Floor, Boston MA 02116

(c)

Item 2(c). Citizenship: RA Capital and the Fund are Delaware limited partnerships. Dr. Kolchinsky and Mr. Shah are United States citizens.

(d)

Item 2(d). Title of Class of Securities: Common Stock, par value $0.0001 per share (“Common Stock”)

(e)

Item 2(e). CUSIP Number: 007002108 Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. The Fund directly holds (i) 6,138,000 shares of Common Stock and (ii) 8,445,333 Pre-funded warrants (“Pre-Funded Warrants”), through which it has the right to acquire 8,445,333 shares of Common Stock subject to a Beneficial Ownership Blocker (as defined below). The shares reported herein for the Reporting Persons represent (i) 6,138,000 shares of Common Stock held directly, and (ii) 1,558,949 shares of Common Stock that the Reporting Persons beneficially own based on the right to acquire, upon the exercise of the Pre-Funded Warrants. The Pre-Funded Warrants are subject to a beneficial ownership blocker (“Beneficial Ownership Blocker”), which precludes the exercise of the Pre-Funded Warrants to the extent that, following exercise, the Reporting Persons, together with its affiliates and other attribution parties, would own more than 9.99% of the Common Stock outstanding. The Reporting Persons are currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in beneficial ownership of more than 7,696,949 shares of Common Stock. The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The beneficial Prospectus Supplement dated January 22, 2024 filed on January 24, 2024; and (ii) 1,558,949 shares of Common Stock of which the Reporting Persons may acquire beneficial ownership upon the exercise of Pre-Funded Warrants as limited by the Beneficial Ownership Blocker. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner

View Full Filing

View this SC 13G filing on SEC EDGAR